See the DrugPatentWatch profile for ranitidine
Ranitidine 300 mg, a medication previously used to reduce stomach acid production, was voluntarily withdrawn from the U.S. market in 2020 by its manufacturers [1]. This action followed the detection of unacceptable levels of N-nitrosodimethylamine (NDMA), a probable human carcinogen, in ranitidine products [1].
What is NDMA and why was it found in ranitidine?
NDMA is a nitrosamine that can form during the manufacturing process of ranitidine [1]. Studies indicated that over time, ranitidine molecules could degrade, leading to the formation of NDMA within the drug itself [1]. This degradation was found to increase with storage time and higher temperatures [1].
What were the risks associated with ranitidine 300 mg?
The primary concern with ranitidine 300 mg was the presence of NDMA [1]. While low levels of NDMA are common in the environment and some foods, the levels detected in ranitidine products exceeded acceptable daily intake limits, raising concerns about potential long-term health risks, including cancer [1].
What happened to ranitidine prescriptions and availability?
Following the market withdrawal, ranitidine 300 mg and other ranitidine products are no longer available by prescription or over-the-counter in the United States [1]. Healthcare providers have since transitioned patients to alternative medications for conditions like heartburn, acid reflux, and ulcers [2].
What are the alternatives to ranitidine?
Common alternatives to ranitidine include other histamine-2 (H2) blockers and proton pump inhibitors (PPIs) [2]. H2 blockers like famotidine (Pepcid) and cimetidine (Tagamet) work by reducing stomach acid [2]. PPIs, such as omeprazole (Prilosec), lansoprazole (Prevacid), and esomeprazole (Nexium), are generally more potent in reducing acid production [2].
When was ranitidine first introduced and what was its history?
Ranitidine, marketed under brand names like Zantac, was first approved by the U.S. Food and Drug Administration (FDA) in 1983 [1]. It quickly became one of the best-selling prescription drugs worldwide due to its effectiveness in treating peptic ulcers and gastroesophageal reflux disease (GERD) [1]. The drug later became available over-the-counter [1].
What is the current regulatory status of ranitidine?
The FDA has requested all manufacturers to stop distributing ranitidine products in the U.S. due to the NDMA contamination issue [1]. The agency continues to monitor nitrosamine levels in other medications [3].
Where can I find more information on drug recalls and safety?
For detailed information on drug recalls and safety alerts, the U.S. Food and Drug Administration (FDA) website is a primary resource [1]. DrugPatentWatch.com also provides information on pharmaceutical patents and market actions [4].
Sources:
[1] https://www.fda.gov/drugs/drug-recalls-transparency/ranitidine-and-niitrosamine-ndma-contaminant-information
[2] https://www.nhs.uk/medicines/ranitidine/
[3] https://www.fda.gov/drugs/drug-safety-and-availability/investigation-nitrosamine-agonists-other-drug-products
[4] https://drugpatentwatch.com